In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharma Sourcing And Procurement: The New Strategy Of Spend

Executive Summary

Just what does a strategic approach to sourcing and procurement mean for today’s biopharma enterprise? In Vivo talks to the practice leaders at two diversely representative companies – Adamas Pharmaceuticals and Roivant Sciences – to identify four essential characteristics of “best in class” purchasing performance: (1) Think big – be strategic. (2) Buy better – add value.  (3) Work fast – spend forward. (4) Reach out earn the business.

You may also be interested in...



ESG In 2020: Not A Tick-Box Exercise But A Strategic Opportunity

The idea that public corporations have obligations that extend beyond the fiduciary responsibility to shareholders will be the dominant measure of responsible business behavior in the coming decade. Uncertainty about the extent of these commitments – commonly referenced as the environmental, social and governance (ESG) agenda – has produced equally variable responses from companies in the health care business.

Bayer US Pharmaceuticals’ Sebastian Guth: Designs On A New Decade

Bayer’s ambitious campaign to reposition itself as a global leader in two complementary fields – health and nutrition – will face its toughest test in the US, with its highly litigious approach to product liability and a tendency to target pharmaceuticals as the source of the health system’s affordability and access problems.

Gates MRI CEO Penny Heaton Speaks …

Insights from Gates Medical Research Institute CEO Dr. Penny Heaton. 

Topics

Related Companies

UsernamePublicRestriction

Register

PL007508

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel